Teresa Brophy Bair Sells 8,804 Shares of Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Teresa Brophy Bair sold 8,804 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $11.18, for a total transaction of $98,428.72. Following the sale, the insider owned 188,139 shares of the company’s stock, valued at approximately $2,103,394.02. The trade was a 4.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Teresa Brophy Bair also recently made the following trade(s):

• On Monday, September 29th, Teresa Brophy Bair sold 8,805 shares of Kura Oncology stock. The stock was sold at an average price of $8.94, for a total transaction of $78,716.70.

Kura Oncology Price Performance

KURA traded up $0.52 on Friday, hitting $11.20. 4,478,689 shares of the company’s stock were exchanged, compared to its average volume of 2,241,571. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12. The stock has a fifty day moving average of $9.46 and a two-hundred day moving average of $7.48. Kura Oncology, Inc. has a twelve month low of $5.41 and a twelve month high of $16.68.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.28). Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.The company had revenue of $20.75 million during the quarter, compared to the consensus estimate of $17.48 million. On average, analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Wall Street Analyst Weigh In

KURA has been the topic of several research reports. JMP Securities reiterated a “market outperform” rating and issued a $24.00 price target on shares of Kura Oncology in a research report on Monday, October 20th. UBS Group boosted their target price on shares of Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Friday. Wedbush restated an “outperform” rating and set a $38.00 target price (up from $36.00) on shares of Kura Oncology in a report on Friday. Zacks Research upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 5th. Finally, Guggenheim started coverage on shares of Kura Oncology in a research report on Thursday, September 4th. They set a “neutral” rating on the stock. Ten equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $25.11.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its position in shares of Kura Oncology by 392.8% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after purchasing an additional 3,072 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Kura Oncology by 127.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after acquiring an additional 3,769 shares during the period. State of Wyoming bought a new position in Kura Oncology during the first quarter worth about $48,000. Merit Financial Group LLC bought a new stake in Kura Oncology in the third quarter valued at $89,000. Finally, Magnetar Financial LLC bought a new stake in shares of Kura Oncology in the 1st quarter worth about $79,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.